Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
President Donald Trump's effect on bank capital rules, crypto policy, antitrust scrutiny, and drug pricing are among key 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback